SEC Probes Continuation Vehicles: What Accredited Investors in GP-Led Funds Must Know Now

TL;DR — What You Need to Know

• The SEC is actively investigating continuation vehicles (CVs) for conflicts of interest, valuation manipulation, and inadequate LP disclosures. This is not a future risk; it is happening now.
• GP-led secondary transactions hit $106 billion in 2025, up 51% year-over-year, making this the fastest-growing and most conflicted corner of private equity.
• Mercer's analysis of approximately 150 GP-led transactions found 59% closed at a NAV discount, averaging 8% below stated value. LPs who sold out left money on the table in most cases.
• Action items for LPs: Request the independent valuation report, demand a fairness opinion, ask your GP to name the secondary buyer, and consult the SEC's 2026 examination priorities for private fund advisers before you sign anything.

According to Reuters (June 24, 2026), the U.S. Securities and Exchange Commission has opened formal probes into continuation vehicles, the GP-led fund restructurings that have become one of private equity's most popular exit tools. The SEC is looking at whether GPs are disclosing conflicts properly, whether valuations are accurate, and whether LPs are being pressured or misled when they face the choice to roll their interest into a new vehicle or cash out at a price the same GP helped set. If you hold an LP interest in any private equity fund that is currently being restructured, or has restructured in the last 24 months, this story is about your money.

What Is a Continuation Vehicle?

A continuation vehicle is a fund structure a GP creates to extend ownership of one or more assets past the original fund's term. The GP transfers the asset from the old fund into a new, separate legal entity. Existing LPs get a choice: take cash and exit, or roll their interest into the new vehicle and stay invested. New investors, typically large secondary market buyers, provide the liquidity that pays out the LPs who want to exit.

The mechanics make sense on paper. A GP holds a portfolio company that is performing well but not yet ready for a full exit. Rather than selling it at a suboptimal time, the GP buys time through a continuation vehicle. LPs who need liquidity get it. LPs who want to stay get the option. Sounds clean.

The problem is who controls every side of this transaction. The GP sets the asset's valuation. The GP selects the secondary buyer. The GP determines the terms of the roll. The GP benefits from continued management fees and carried interest in the new vehicle. That is a conflict of interest built directly into the architecture of the deal, and that is exactly what the SEC is now scrutinizing.

The market for these structures has grown fast. Evercore's 2025 Secondary Market Report puts GP-led secondary transaction volume at $106 billion in 2025, up 51% from $70 billion in 2024. The total private capital secondary market crossed $200 billion for the first time. Entering 2026, there is an estimated $215 billion in dry powder targeting this space. The scale of LP exposure is enormous, and it is growing faster than the regulatory guardrails around it. For a fuller picture of how these structures work, see our guide to GP-led secondaries and continuation funds.

Why the SEC Is Watching

The SEC did not randomly pick continuation vehicles as a target. The agency has watched the GP-led secondary market triple in size over four years while the legal and disclosure standards governing these transactions remained largely unchanged. The structural conflict at the heart of every CV is the core issue.

In a traditional asset sale, there is a buyer and a seller with opposite economic interests. In a continuation vehicle, the GP is effectively on both sides. As the seller, the GP owes the existing LPs a duty to get fair value for the asset. As the party who selects the buyer and negotiates on behalf of the new vehicle, the GP has every financial incentive to keep the price low enough that the new vehicle retains upside. The GP also continues collecting management fees and carried interest in the new structure, which only exists if enough LPs roll over rather than cash out.

This creates pressure on the exit price that most LPs do not fully understand when they receive the offer documentation. Mercer's review of approximately 150 GP-led transactions between 2021 and 2025 found that 59% closed at a discount to NAV, 40% at par, and just 1% at a premium. The average discount was 8%. Average management fees in these vehicles ran 0.85%. In the majority of cases, LPs who sold out accepted less than stated book value, and in many cases that book value itself was set by the GP who was selling.

Valuation opacity compounds this problem. Private equity assets are not marked to market daily. A GP has considerable discretion in how it values a portfolio company. If that GP knows a continuation vehicle transaction is coming, there is a financial incentive to keep valuations conservative in the quarters leading up to the deal, so the offer price looks fair relative to NAV, even if it would look cheap relative to what a strategic buyer might pay in an arm's-length sale.

What the SEC Is Investigating Specifically

David Woodcock, who leads the SEC's Enforcement Division, has made the agency's focus explicit in recent public remarks. He identified four areas of concern in private markets: liquidity, fees, valuations, and conflicts of interest. Continuation vehicles touch all four simultaneously.

On disclosures, the SEC is asking whether LPs received sufficient information to make an informed decision at the time they were offered the roll-or-exit choice. Did the offer documents explain who the secondary buyer was and what relationship, if any, they had with the GP? Did they disclose the fee terms of the new vehicle? Did they explain the independent process, if one existed, used to arrive at the transaction price?

On valuations, the agency is examining whether the NAV figures used to set transaction prices were calculated consistently with prior periods, and whether the GP's third-party valuation firm had any conflicts of its own. A GP that has used the same valuation firm for a decade has a relationship that can, over time, create subtle incentive alignment, even without explicit wrongdoing.

On conflicts, the SEC wants to know whether GPs made full disclosure of their own financial interest in the outcome. A GP that stands to collect an additional three to five years of management fees from a new continuation vehicle has a direct financial stake in LP participation rates. That is material information an LP needs before deciding to roll.

The SEC's examination division published its 2026 priorities for private fund advisers earlier this year, and continuation vehicles were listed explicitly. The enforcement division is now a step beyond examinations, running active investigations that include document requests, witness interviews, and the potential for formal enforcement actions. You can review what the SEC flagged in full at our breakdown of the 2026 exam priorities for private fund advisers.

What This Means for Your LP Position

If you are an LP in a private equity fund that has launched or is considering a continuation vehicle, you need to act before you receive the official offer document, not after. Once the formal election period opens, the timeline compresses and GPs have little incentive to slow down for questions.

Start with the valuation. Request the full independent valuation report for every asset going into the continuation vehicle. Not a summary. The full report, including methodology, comparable transactions used, and the name and engagement terms of the third-party valuation firm. If your LP agreement does not give you that right, note it and ask your GP to provide it anyway. A GP that refuses to share the independent valuation for an asset it is asking you to roll into is telling you something important.

Ask for a fairness opinion. Many GP-led transactions do not include one, and they are not legally required. A fairness opinion from an independent financial adviser, not the GP's placement agent, provides meaningful protection. If your GP did not obtain one, ask why.

Ask who the secondary buyer is and what their relationship with the GP looks like. Prior fund relationships or co-investment history between the GP and the buyer are not necessarily disqualifying, but you need that information to judge whether the price was truly arm's length.

Review the fee terms of the new vehicle carefully. A continuation vehicle with a lower preferred return hurdle than your original fund is a direct transfer of economic value from you to the GP. Consult legal counsel before signing anything. The election window is typically 30 to 45 days, which is enough time to get an attorney to review the documents.

This is also a moment to examine your overall private credit allocation. The expansion of GP-led secondaries into credit assets, which grew from 5% of activity in 2024 to 11% in 2025, means LP exposure to these conflicts is no longer just a private equity issue. If you hold LP interests in private credit funds, the same structural risks apply. Our analysis of private credit in 2026 covers the yield and risk profile in more detail.

The Blue Owl and BlackRock Context

Two names appear repeatedly in the background of this SEC review: Blue Owl Capital and BlackRock. Neither company has been named as a formal target of the current investigation, and nothing in the Reuters reporting suggests either has done anything wrong. But their scale in the continuation vehicle and GP-led secondary market makes them significant reference points for regulators trying to understand how these transactions work in practice.

Blue Owl Capital has built a substantial business around GP-led secondaries and continuation structures. Its transactions are now being studied as data points to understand market norms and where deviations from those norms occur. When a firm operates at this volume, regulators treat its deal history as a map of the market.

BlackRock's scale in private markets, accelerated by its acquisition of Global Infrastructure Partners, means its disclosure practices in GP-led transactions effectively set a market standard. When that standard is questioned by the SEC, the implications spread across every firm running similar deals.

Abu Dhabi Investment Council (ADIC) and Energy & Minerals Group (EMG) have appeared in the secondary market context as large institutional participants. The fact that sophisticated institutional LPs with full-time investment teams have raised concerns about valuations and conflict disclosures tells you how opaque these transactions remain, even at the top of the market.

Paul Atkins, now SEC Chair, was expected by some to bring a lighter touch to private markets regulation. The Woodcock-led enforcement push into continuation vehicles suggests the agency is not backing off.

Jeff's Take

I have spent years watching private equity structures evolve. Continuation vehicles are the most structurally conflicted instrument I have seen become mainstream. I do not think they are inherently fraudulent. But the disclosure conditions under which they are sold to LPs are often not adequate for informed decision-making, and the SEC is right to look closely.

If I were an LP facing a continuation vehicle election today, I would not sign anything until I had reviewed the full independent valuation report and spoken to legal counsel. I would compare the proposed price to what an open-market sale might generate by asking the GP directly: how many secondary buyers were approached, what process did Evercore or a comparable placement agent run, and what was the range of bids received? If the GP cannot document a competitive process, that absence is itself informative.

I would treat any GP who pushes back on basic disclosure requests as a red flag. A GP with nothing to hide answers these questions. One who points you to a data room while resisting direct answers is managing the process for their own benefit, not yours.

This could blow up because the SEC investigation creates liability exposure that GPs did not price into their 2024 and 2025 transactions. If the agency finds systematic disclosure failures, LP agreements may not protect GPs from rescission claims. That risk extends to the new continuation vehicle investors who bought into these structures. They may face legal challenge from the original LPs they paid out.

The $106 billion GP-led secondary market is not going away. The incentives are too strong. But the era of minimal disclosure and no independent oversight is ending. Treat every continuation vehicle offer with the same scrutiny you would give any major financial decision, because that is exactly what it is.

For those thinking about liquidity alternatives beyond GP-led structures, our piece on interval funds and accredited investor liquidity provides a grounded comparison of what those structures actually offer.

Additional data on secondary market volume and deal structures can be found in the SEC's own briefing on the 2025 secondary market, which puts the $226 billion total volume and $215 billion in projected dry powder in regulatory context.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.